Clinical deterioration in established heart failure: What is the value of BNP and weight gain in aiding diagnosis?
- 1 October 2005
- journal article
- research article
- Published by Wiley in European Journal of Heart Failure
- Vol. 7 (6), 953-957
- https://doi.org/10.1016/j.ejheart.2005.06.003
Abstract
Weight gain and increase in B-Type Natriuretic Peptide have been advocated as means of aiding diagnosis of heart failure. However, there are few data to support the use of these criteria in diagnosing clinical deterioration in patients with established disease. This prospective study examines the sensitivity and specificity of absolute and relative changes in BNP and weight in determining the early onset of clinical deterioration in patients with established heart failure. All patients who presented to the outpatient clinic with completed self-reported daily weight books, baseline BNP measurement, outpatient BNP measurement and assessment by a cardiologist blinded to BNP and weight were included. Each patient was determined as clinically stable (CS) or in clinical deterioration (CD). Receiver operating characteristic (ROC) curves and sensitivity and specificity calculations for various absolute and relative BNP and weight changes were carried out. Weight and BNP changes were examined in 34 CS presentations (mean age 69.5+/-16.1 years) and 43 CD presentations (mean age 70.0+/-10.6 years). ROC analysis demonstrated that neither weight nor BNP changes in absolute or relative values predicted clinical deterioration in this study population adequately (AUC values ranging from 0.64 to 0.66). These data demonstrate that increase in body weight and BNP in isolation are not sensitive in assessing clinical deterioration in established heart failure. These observations may need to be emphasized in patient education and to physicians involved in assessment of heart failure patients.Keywords
This publication has 19 references indexed in Scilit:
- N-Terminal–Pro-Brain Natriuretic Peptide Predicts Outcome After Hospital Discharge in Heart Failure PatientsCirculation, 2004
- NT‐proBNP and the diagnosis of heart failure: a pooled analysis of three European epidemiological studiesEuropean Journal of Heart Failure, 2004
- Biological variation of the natriuretic peptides and their role in monitoring patients with heart failureEuropean Journal of Heart Failure, 2004
- B-type natriuretic peptide in cardiovascular diseaseThe Lancet, 2003
- Rapid Measurement of B-Type Natriuretic Peptide in the Emergency Diagnosis of Heart FailureThe New England Journal of Medicine, 2002
- Guidelines for the diagnosis and treatment of chronic heart failurePublished by Oxford University Press (OUP) ,2001
- Elimination of early rehospitalization in a randomized, controlled trial of multidisciplinary care in a high‐risk, elderly heart failure population: the potential contributions of specialist care, clinical stability and optimal angiotensin‐converting enzyme inhibitor dose at dischargeEuropean Journal of Heart Failure, 2001
- Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Comparison with plasma angiotensin II and endothelin-1Published by Oxford University Press (OUP) ,1999
- Biochemical detection of left-ventricular systolic dysfunctionThe Lancet, 1998
- Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure.Circulation, 1994